Injection of SHR-A1811 Versus TAS-102 in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Conditions: Advanced Colorectal Cancer Interventions: Drug: SHR-A1811; Drug: TAS-102 Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Conditions: Gastric Cancer; Organoid; Neoadjuvant Therapy Interventions: Drug: Oxaliplatin Sponsors: Dong Bing Zhao Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Conditions: Gastric Cancer Interventions: Drug: Tislelizumab; Drug: Oxaliplatin; Drug: Levo-Leucovorin; Drug: 5-fluorouracil; Drug: Irinotecan Hydrochloride; Drug: Paclitaxel Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
Conditions: Gastric Cancer Interventions: Drug: Oxaliplatin and capecitabine/ S-1 and capecitabine Sponsors: The First Affiliated Hospital of Zhengzhou University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma
Conditions: Locally Advanced Gastric Adenocarcinoma Interventions: Drug: adebrelimab, S-1 and oxaliplatin; Drug: S-1 and oxaliplatin Sponsors: Yang Jianjun, PhD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS < 5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma Interventions: Drug: M108 monoclonal antibody; Drug: Placebo; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: FutureGen Biopharmaceutical (Beijing) Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Conditions: Neoadjuvant Chemotherapy; Resectable Pancreatic Cancer Interventions: Drug: irinotecan liposome + oxaliplatin + 5-FU / LV; Drug: Adebellizumab Sponsors: Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
Conditions: Previously AG Chemotherapy Treated Pancreatic Cancer Interventions: Drug: Zimberelimab; Drug: Oxaliplatin; Drug: S-1; Drug: Irinotecan Sponsors: Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 12, 2023 Category: Research Source Type: clinical trials
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma Interventions: Drug: BEBT-908 for Injection; Drug: Rituximab Injection; Drug: Gemcitabine Hydrochloride for Injection; Drug: Oxaliplatin Injection; Drug: Etoposide Injection; Drug: Ifosfamide for Injection; Drug: Carboplatin Injection Sponsors: BeBetter Med Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Camrelizumab Combined With Apatinib ćChemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
Conditions: Gastroesophageal Junction Adenocarcinoma (Siewert II-III) Interventions: Drug: Camrelizumab+Apatinib+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Capecitabine; Drug: oxaliplatin; Drug: Disitamab Vedotin; Drug: Toripalimab Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Conditions: Advanced Solid Tumor Interventions: Biological: JS015; Biological: Toripalimab; Biological: Paclitaxel; Drug: Irinotecan; Drug: Capecitabine; Drug: Oxaliplatin; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin; Drug: Gemcitabine; Drug: Albumin-Bound Paclitaxel Sponsors: Shanghai Junshi Bioscience Co., Ltd.; Sponsor GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
Conditions: Colonic Neoplasms; Neoadjuvant Therapy; Immune Checkpoint Inhibitors Interventions: Drug: Anti-PD-1 monoclonal antibody; Drug: Oxaliplatin; Drug: Capecitabine 500 MG; Procedure: Colectomy Sponsors: First Affiliated Hospital of Guangxi Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Conditions: GastroEsophageal Cancer; Gastric Cancer Interventions: Drug: Neratinib; Drug: Trastuzumab; Drug: Oxaliplatin; Drug: 5-Fluorouracil + leucovorin; Drug: Pembrolizumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Puma Biotechnology, Inc.; National Comprehensive Cancer Network Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Drug: Durvalumab; Drug: Oxaliplatin; Drug: Irinotecan; Drug: Calcium folinate (leucovorin); Drug: Fluorouracil; Drug: Pegylated G-CSF Sponsors: Australasian Gastro-Intestinal Trials Group; The University of New South Wales; Walter and Eliza Hall Institute of Medical Research Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
